NEW YORK (360Dx) – Progentec Diagnostics is developing a protein biomarker platform and assay that's showing promise in predicting lupus flares, which are painful for patients and can occur without warning or a clear cause.

The firm's chances of reaching commercialization and achieving adoption have been improved by its signing of strategic investor Mayo Clinic Ventures, an organization with a cadre of physicians that could benefit from use of the test, Scott Meacham, CEO of non-profit investment funding firm i2E and an investor in Progentec, said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.